Tonazocine

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Tonazocine
Tonazocine-2D-by-AHRLS-2012.png
Tonazocine-3D-balls-by-AHRLS-2012.png
Clinical data
ATC code
  • None
Legal status
Legal status
  • In general: non-regulated
Identifiers
CAS Number
PubChem CID
ChemSpider
UNII
Chemical and physical data
Formula C23H35NO2
Molar mass 357.530 g/mol
3D model (JSmol)

Tonazocine (WIN-42,156) is an opioid analgesic of the benzomorphan family which made it to phase II clinical trials for the treatment of postoperative pain,[1] but development was apparently ceased and ultimately it was never marketed. Tonazocine is a partial agonist at both the mu-opioid and delta-opioid receptors, but acting more like an antagonist at the former and more like an agonist at the latter.[2][3] It lacks most of the side effects of other opioids such as adverse effects on the cardiovascular system and respiratory depression, but it can cause sedation (although to a lesser degree of typical opioids), and in some patients it may induce hallucinations (probably via binding to and activating the κ-opioid receptor).[4]

See also[edit]

References[edit]

  1. ^ American Chemical Society. Division of Medicinal Chemistry (1990). Annual Reports in Medicinal Chemistry. Academic Press. p. 12. ISBN 978-0-12-040525-1. Retrieved 30 November 2011. 
  2. ^ Ward SJ, Pierson AK, Michne WF (February 1985). "Pharmacological profiles of tonazocine (Win 42156) and zenazocine (Win 42964)". Neuropeptides. 5 (4-6): 375–8. PMID 2860595. doi:10.1016/0143-4179(85)90032-0. 
  3. ^ Hudzik TJ, Howell A, Payza K, Cross AJ (May 2000). "Antiparkinson potential of delta-opioid receptor agonists". European Journal of Pharmacology. 396 (2-3): 101–7. PMID 10822062. doi:10.1016/S0014-2999(00)00209-0. 
  4. ^ Aronson, Jeffrey K. (30 November 2009). Meyler's Side Effects of Analgesics and Anti-inflammatory Drugs. Elsevier. p. 154. ISBN 978-0-444-53273-2. Retrieved 30 November 2011.